HeartBeam, Inc.

NasdaqCM BEAT

HeartBeam, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2024: USD -28.01 M

HeartBeam, Inc. EBIT is USD -28.01 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -24.96% change year over year. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.

HeartBeam, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -22.41 M, a -5.38% change year over year.
HeartBeam, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -21.27 M, a -844.82% change year over year.
HeartBeam, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -2.25 M, a -135.41% change year over year.
HeartBeam, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 6.36 M, a -88.89% change year over year.

Key data

Date	EBIT	EBITDA	Net Income	EPS (Diluted)

NasdaqCM: BEAT

HeartBeam, Inc.

CEO	Mr. Robert P. Eno
IPO Date	Nov. 11, 2021
Location	United States
Headquarters	2118 Walsh Avenue
Employees	15
Sector	Health Care
Industries Telehealth Medical Instruments

Description

HeartBeam, Inc., a medical technology company, primarily focuses on telemedicine solutions for the detection and monitoring of cardiac disease outside a healthcare facility setting. The company also focuses on providing diagnostic data to physicians with care management of patients with cardiovascular disease. Its telehealth product comprises a credit card sized electrocardiogram machine and a cloud-based diagnostic software system to address the rapidly growing field of remote patient monitoring. The company was incorporated in 2015 and is headquartered in Santa Clara, California.

Key trends

Past 5 years